Inflammation and therapeutic vaccination in CNS diseases. - Wikidata - awgldk - TriplyDB

Inflammation and therapeutic vaccination in CNS diseases.

Inflammation and therapeutic vaccination in CNS diseases.

http://www.wikidata.org/entity/Q35030005

about

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-α pathway Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease Dynamics of the meningeal CD4(+) T-cell repertoire are defined by the cervical lymph nodes and facilitate cognitive task performance in mice.In vivo imaging of neuroinflammation in schizophrenia Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy.Constitutively active NF-kappaB triggers systemic TNFalpha-dependent inflammation and localized TNFalpha-independent inflammatory disease.Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice.Curcumin inhibits the AKT/NF-κB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line.Antioxidant therapy in Alzheimer's disease: theory and practice.Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology.Simvastatin enhances immune responses to Aβ vaccination and attenuates vaccination-induced behavioral alterations Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset Role of TNFα Induced Inflammation in Delay Eyeblink Conditioning in Young and Aged Rats.Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: a case series.A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis.High dynamic range characterization of the trauma patient plasma proteome Immunomodulation and vaccination for atherosclerosis.Protein misfolding in neurodegenerative diseases.Emerging chlamydial infections.Multi-Shell Hybrid Diffusion Imaging (HYDI) at 7 Tesla in TgF344-AD Transgenic Alzheimer Rats.Understanding Alcoholism Through microRNA Signatures in Brains of Human Alcoholics.Biomarkers of Alzheimer disease in plasma Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis.Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects?Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice.Refining an Alzheimer's vaccine to avoid an inflammatory response.Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.Src protein tyrosine kinase family and acute inflammatory responses.Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model Interleukin-10 is a critical regulator of white matter lesion containment following viral induced demyelination Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.The PPAR-gamma Agonist 15-Deoxy-Delta-Prostaglandin J(2) Attenuates Microglial Production of IL-12 Family Cytokines: Potential Relevance to Alzheimer's Disease.Gene therapy for misfolding protein diseases of the central nervous system.Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study.Design of a novel thiophene inhibitor of 15-lipoxygenase-1 with both anti-inflammatory and neuroprotective properties

P2860

Q24534813-7B457FF8-0FAD-4800-B2B9-D2010001D28D Q24670380-CB5E4D35-4272-4534-8BA8-38EC3C726106 Q28387166-5A0B1E1A-6CBA-4602-BB90-D6E9FA00F183 Q28387661-22965A5E-5BBA-4784-98DD-16B5A9525335 Q30054419-E969DA14-ABA5-443A-8F34-9196ED866C52 Q30409867-712E37C2-C7A3-470F-8422-4FA5AD935610 Q30966978-26B20D41-2880-4D7E-96A0-B3402C08427F Q33249100-EB8D69D8-0C57-4DF3-AA8A-777139356F14 Q33659872-106B968E-E217-44BB-97A2-39ED8FA4D393 Q33797754-6C74303F-D3AF-422F-A279-9BA6A4F0B6E9 Q33803989-97AF8701-1E11-40B7-8B1C-63D25079AA19 Q34066474-D9184B88-61EE-4E6B-9542-7616F051C076 Q34096571-8EFF3506-4A6F-4FE6-BA04-43142AE30846 Q34143153-9F23E204-97CE-4D0D-9889-B9C138D5ED35 Q34496393-1837A741-1979-48B9-9C64-260573FF76B3 Q34982943-59A6750D-4FC7-467A-AB3A-713E7059DAFD Q35156471-E8169AD4-FB0C-483E-B3AE-B1FB5C9FE4C3 Q35183183-4B1A40B6-EA23-407E-8757-5B1CAA28663B Q35250397-E3E1A558-FFE8-4540-9B0B-B85AC240278E Q35554193-F879E30A-4711-4DAA-8E17-E1DA579A7532 Q35613820-64F9DE97-5C4A-4DEE-AD05-B0BC6337BB45 Q35753555-3EE512D3-1D8A-4D79-B6BC-8CCDE8649747 Q35790921-10FA8F8D-C622-43C9-9F7F-D4CB9E9DD319 Q35828718-7378C0EE-9633-41C9-B1D5-A4D3B56661E3 Q35873150-B249E664-2263-467A-BE6E-4AC1B9BF4385 Q35878186-7EDFD2A2-3124-4AA0-AE2F-1831810CDEE2 Q36045288-FF8CF8E5-8D10-4043-A2B5-2E4F6A590AAB Q36055389-6C7747A0-8DB3-4057-887B-E4B83A694062 Q36107258-D07007EC-DB06-4865-8E81-AE6BBEC8928D Q36119066-FA415367-19B1-481F-B3DC-C3CB6A1FD17E Q36161226-DFCA2FB3-ED26-4D12-9EE3-50F3C9A7CA1F Q36401406-ECB5CF5E-4114-435E-89AD-BA5B32B1384F Q36438267-3FAACF69-7842-4D2C-90BC-DD9E9B2A2E71 Q36576263-F9370152-A4F9-49B3-8449-B5A687F84202 Q36584434-C74E4982-138A-4670-A575-BF8BEB9A97BF Q36631376-7AA6DA03-5176-4B52-8D3C-2E5B577524DB Q36742787-C7368B0F-263B-40B2-9D19-65DAAE181063 Q36983203-B794F99A-B02E-48E3-881D-B707F68FB309 Q37131312-8C00DF42-3C03-429F-BB5B-94DEC35750A5 Q37229746-B35040E3-603A-4023-9AEC-9A9FEB3A974A

P2860

Inflammation and therapeutic vaccination in CNS diseases.

http://www.wikidata.org/entity/Q35030005

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Inflammation and therapeutic vaccination in CNS diseases.

@ast

Inflammation and therapeutic vaccination in CNS diseases.

@en

type

label

Inflammation and therapeutic vaccination in CNS diseases.

@ast

Inflammation and therapeutic vaccination in CNS diseases.

@en

prefLabel

Inflammation and therapeutic vaccination in CNS diseases.

@ast

Inflammation and therapeutic vaccination in CNS diseases.

@en

P1433

Q35030005-697C1D2A-342D-4134-AD73-3C74C90EFA04

P1476

Q35030005-6A1D77C3-B694-4CA1-82C5-8332C8F7CAFC

P2093

Q35030005-1C0DFC9A-77A7-45E5-BE95-BB7CBFC1F597

Q35030005-5D3F5615-2711-4FFD-AB7B-3F5A6CB4ED13

P2860

Q35030005-01D09E27-93A7-492B-8B67-4C1BE703ED1C

Q35030005-05405422-3C5A-47FB-9F9B-BB9270717A66

Q35030005-09E2696F-5BC7-4803-B5CB-6DF572BEAED8

Q35030005-0CEB3ED1-56A8-4F4C-8779-1DEF41124F25

Q35030005-1A685848-0CDD-42B4-B372-7D689304C2EA

Q35030005-2013490F-F37B-489D-A524-BEA7C5F6E5A6

Q35030005-2A1AFFE9-5D1E-4202-A8EA-18F01C4F5717

Q35030005-33CD4758-0FB2-4FED-AED2-0D86E0D5A0A7

Q35030005-39F85ED0-DB86-466C-9004-4D3A0A3C11E5

Q35030005-3DCAF4CA-3565-4514-B58E-8E7427653626

P2888

Q35030005-DBC9391F-43BE-4D0D-A679-09D6C4E3BF5D

P304

Q35030005-F31A8425-B61A-47B4-BEBE-B7F8086C8552

P31

Q35030005-E3792B29-07AA-4418-8B31-4AD463A4C31B

P356

Q35030005-AE97A5FF-53C2-46CA-8FFA-B02D6C1F26CB

P407

Q35030005-F3D96BD8-15A3-48C2-A101-94D34445E7C5

P433

Q35030005-7387E19F-4FF8-439D-AE6E-09E08532A32C

P478

Q35030005-6E946125-A167-4C63-AA1F-BC9D4EEF1544

P577

Q35030005-14ECAE2C-4442-4D10-BB96-73934D280B4B

P5875

Q35030005-B7E562D5-3E9F-4292-B1A2-86A11D9A23EA

P6179

Q35030005-B9119237-FD3A-4D18-96D3-4D7704670D5A

P698

Q35030005-4CFCA25A-1FF6-4CA8-9022-B27B3D4B640E

P356

P1433

P1476

Inflammation and therapeutic vaccination in CNS diseases.

@en

P2093

Dennis J Selkoe

http://www.w3.org/2001/XMLSchema#string

Howard L Weiner

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and Alzheimer's disease

The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

The role of magnetic resonance techniques in understanding and managing multiple sclerosis.

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice.

P2888

P304

879-884

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE01325

http://www.w3.org/2001/XMLSchema#string

P407

P433

6917

http://www.w3.org/2001/XMLSchema#string

P478

420

http://www.w3.org/2001/XMLSchema#string

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10983147

http://www.w3.org/2001/XMLSchema#string

P6179

1038245003

http://www.w3.org/2001/XMLSchema#string

P698

12490962

http://www.w3.org/2001/XMLSchema#string